• First Patient enrolled in the SAKK Investigator-Initiated Phase 1b trial of Docetaxel Micellar in Advanced Prostate Cancer

XR-17 is Oasmia’s proprietary delivery platform

CEO corner

Get to learn more about Francois Martelet, our CEO

Oasmia Pharmaceutical published its interim report for the second quarter of 2021 on August 19, 2021, at 08.00 am CEST.

The company will hold a conference call and an online presentation on the same day at 10.00 am CEST. The call will be hosted by CEO Francois Martelet and CFO Fredrik Järrsten. The presentation will be in English.

The Share

Oasmia and Elevar sign a global strategic partnership for the commercialization of Apealea®

Annual Report 2020